COVINGTON, Ky. — Bexion Pharmaceuticals announced Thursday that the company has added Bob Savage to its board of directors.
Savage brings to the Bexion board more than 40 years of experience in marketing, sales, drug development, operation and business development in the pharmaceuticals and biotechnological industries. His areas of expertise include clinical development, go-to-market strategy, regulatory affairs, manufacturing, quality assurance, sales, marketing, talent management, executive coaching, business development, M&A and P&L management.
Savage has held leadership positions with organizations including Pharmacia Corp., Johnson & Johnson and Hoffmann La-Roche. As Group VP and president of the Worldwide General Therapeutics & Inflammation Business with Pharmacia, he held global responsibility for a portfolio with an annual net income of more than $5 billion. In the role of Worldwide Chairman, Pharmaceuticals Group with Johnson & Johnson, Savage oversaw a business unit with over $11 billion in annual sales and 43,000 employees.
As an experienced board member, Savage has been a director with over a dozen organizations including Humanigen, Depomed, The Medicines Company, Medworth Acquisition Corporation, Savient Pharmaceuticals, Panacos Pharmaceuticals, Epicept Corporation, Noven Pharmaceuticals, Vela Pharmaceuticals, The Neurological Institute of New Jersey, The Epilepsy Foundation of America, and Robert Wood Johnson Medical School.
“We are very excited to have someone with Bob’s depth of pharmaceutical knowledge join the Bexion Board of Directors,” stated Chuck Scheper, Bexion board chairman. “His breadth of experience will contribute to Bexion’s ongoing success as we progress with our clinical development plan.”
“Bexion is in an extraordinary position in the oncology market with a first-in-class compound targeted at some of the most difficult to treat cancer types,” said Savage. “Their ongoing work in the treatment of children with rare tumors is particularly significant given the lack of effective treatments for many of these tumor types. I look forward to the opportunity to bring my experience to bear on moving all programs underway successfully forward.”